Eledon Pharmaceuticals, Inc.

ELDN

Eledon Pharmaceuticals, Inc.

ELDN

Insider Sentiment (TTM):

Last Purchase:2024-05-09Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:41,802,053Shares Outstanding:112,424,211Institutional Ownership Pct.:37.18%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	7	6	23	4	6	8	21	7	26	6	5	4
Short Term Investments	82	105	111	90	102	116	120	71	58	37	46	56
Prepaid Expense And Other Assets Current	4	2	2	3	4	3	4	3	4	5	5	3
Assets Current	93	114	136	96	111	128	144	82	87	48	56	63
Operating Lease Right Of Use Asset	0	1	1	1	1	1	1	0	1	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	126	147	169	130	145	161	177	115	120	81	89	96
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	7	4	5	6	3	6	6	2	2	1	0
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Accrued Liabilities And Other Liabilities	8	7	14	9	8	6	5	6	4	2	3	2
Liabilities Current	12	13	18	14	14	9	12	12	6	4	4	3
Deferred Income Tax Liabilities Net	2	2	2	2	2	2	2	2	2	2	2	2
Operating Lease Liability Noncurrent	0	0	0	0	0	1	1	0	0	-	0	0
Warrants And Rights Outstanding	40	30	11	22	23	35	45	24	121	-	76	56
Liabilities	54	46	32	39	39	47	59	39	129	96	82	60
Temporary Equity
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	505	485	482	426	424	421	474	331	324	328	271	325
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	-0	0	0	-	-	-	-
Retained Earnings Accumulated Deficit	-472	-440	-401	-391	-373	-362	-356	-311	-388	-343	-319	-289
Stockholders Equity	33	45	81	35	50	59	62	20	-64	-70	-48	36
Liabilities And Stockholders Equity	126	147	169	130	145	161	177	115	120	81	89	96
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	-	-	-	-	-	5	5	5	5	5	5	5
Temporary Equity Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	-	-	-	-	-	-
Temporary Equity Shares Authorized	5	5	5	5	5	5	-	-	-	-	-	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	300	300	300	300	200	200	200	200	200	200	200	200
Common Stock Shares Issued	81	76	75	60	60	60	60	41	39	25	24	24
Shares Outstanding	81	76	75	60	60	60	60	41	39	25	24	24

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-12.11%	1.80%	-12.11%	-	-	-	-	-	-	-	-	-
2025	8.83%	8.83%	19.43%	4.23%	9.23%	66.15%	-10.23%	-7.95%	25.00%	8.77%	36.14%	19.65%
2024	10.98%	-0.60%	10.18%	-3.81%	-2.72%	75.32%	-4.56%	0.21%	-6.22%	-14.53%	-15.99%	-10.47%
2023	-	-	-	-	-	-	-0.87%	56.52%	58.26%	-9.71%	46.60%	47.09%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.90	8.44	7.40	6.74	8.12	13.91	12.42	6.53	14.48	11.30	14.41	21.73
Quick Ratio	7.53	8.25	7.27	6.53	7.84	13.60	12.11	6.26	13.88	10.09	13.12	20.56
Working Capital	81.30M	100.12M	117.34M	82.01M	97.69M	118.53M	132.15M	69.02M	81.20M	43.73M	52.23M	60.09M
Leverage & Debt
Debt to Equity	1.64	1.03	0.40	1.10	0.77	0.79	0.50	1.89	-2.01	-1.36	-1.69	1.70
Debt Ratio	0.43	0.32	0.19	0.30	0.27	0.29	0.33	0.34	1.07	1.18	0.92	0.63
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.87	-0.70	-0.56	-0.72	0.20	-0.24	-0.75	-0.80	-2.57	-4.31	-4.73	-4.83
Free Cash Flow Per Share TTM	-0.65	-0.61	-0.76	-0.87	-0.84	-0.71	-0.97	-0.72	-0.90	-1.28	-1.61	-1.33
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-754.35%	323.88%	26.07%	25.36%	-113.95%	-85.66%	-68.95%	-69.47%	-25.34%	45.59%	32.48%	277.26%
EPS Growth (1Y)	-544.31%	190.79%	-25.22%	-15.60%	-107.64%	-94.42%	-84.25%	-82.39%	-57.61%	-30.64%	-23.13%	79.55%
Valuation Metrics
P/E TTM	-4.52	-4.40	-2.71	-3.61	13.81	-14.09	-5.53	-2.93	-1.03	-0.48	-0.38	-0.28
P/B TTM	13.56	7.74	1.52	5.65	4.15	4.44	1.69	6.35	-1.74	-0.88	-0.91	1.15
Market Cap	447.71M	346.27M	123.57M	199.83M	209.09M	261.46M	200.00M	129.35M	111.62M	61.78M	44.31M	41.06M
Enterprise Value	440.91M	340.11M	118.67M	196.17M	203.35M	252.96M	179.45M	122.59M	85.58M	56.12M	39.70M	37.40M
Calculated Values
Free Cash Flow TTM	-73.86M	-68.89M	-62.34M	-67.24M	-64.53M	-54.59M	-47.27M	-37.42M	-37.90M	-38.34M	-39.53M	-39.88M
Net Debt	-6.80M	-6.15M	-4.90M	-3.67M	-5.74M	-8.50M	-20.55M	-6.75M	-26.04M	-5.66M	-4.61M	-3.67M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-05-09Purchase

Owner: Bvf, Inc/Il, Biotechnolog…

Title: -

Shares: 1,927,937

Price/Share: -

Value: -

Shares Owned: 3,361,803

Relationship: Other

Ownership: Direct

2023-05-05Purchase

Owner: Biotechnology, Value Trad…

Title: -

Shares: 1,978,932

Price/Share: -

Value: -

Shares Owned: 2,330,418

Relationship: Other

Ownership: Direct

2022-11-23Purchase

Owner: Perrin, Steven

Title: President

Shares: 1,000

Price/Share: $2.60

Value: $2,600.00

Shares Owned: 1,000

Relationship: Director,Officer

Ownership: Direct

2021-12-20Purchase

Owner: Gros, David-Alexandre C

Title: Chief Executive Officer

Shares: 2,000

Price/Share: $4.48

Value: $8,960.00

Shares Owned: 9,000

Relationship: Director,Officer

Ownership: Direct

2021-08-17Purchase

Owner: Gros, David-Alexandre C

Title: Chief Executive Officer

Shares: 4,000

Price/Share: $6.21

Value: $24,840.00

Shares Owned: 7,000

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-05-09	Bvf, Inc/Il, Biotechnolog…	Other	-	Direct	Purchase	1,927,937	-	-	3,361,803	4
2023-05-05	Biotechnology, Value Trad…	Other	-	Direct	Purchase	1,978,932	-	-	2,330,418	4
2022-11-23	Perrin, Steven	Director,Officer	President	Direct	Purchase	1,000	2.60	$2,600.00	1,000	4
2021-12-20	Gros, David-Alexandre C	Director,Officer	Chief Executive Officer	Direct	Purchase	2,000	4.48	$8,960.00	9,000	4
2021-08-17	Gros, David-Alexandre C	Director,Officer	Chief Executive Officer	Direct	Purchase	4,000	6.21	$24,840.00	7,000	4
2021-06-11	Little, Paul Sean	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	10,000	8.87	$88,700.00	10,000	4
2021-06-09	Gros, David-Alexandre C	Director,Officer	Chief Executive Officer	Direct	Purchase	3,000	8.01	$24,030.00	3,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

37.18%

Inst. Shares: 41,802,053

Shares Outstanding: 112,424,211

2025-12-31

52.98%

Inst. Shares: 43,355,330

Shares Outstanding: 81,836,246

2025-09-30

47.14%

Inst. Shares: 36,370,312

Shares Outstanding: 77,156,068

2025-06-30

52.64%

Inst. Shares: 40,613,505

Shares Outstanding: 77,156,068

2025-03-31

49.49%

Inst. Shares: 38,166,521

Shares Outstanding: 77,126,763

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	41,802,053	112,424,211	37.18%
2025-12-31	43,355,330	81,836,246	52.98%
2025-09-30	36,370,312	77,156,068	47.14%
2025-06-30	40,613,505	77,156,068	52.64%
2025-03-31	38,166,521	77,126,763	49.49%
2024-12-31	38,327,406	48,543,787	78.95%
2024-09-30	18,434,030	51,945,920	35.49%
2024-06-30	18,208,013	42,278,411	43.07%
2024-03-31	9,439,573	29,989,400	31.48%
2023-12-31	9,012,338	24,619,197	36.61%
2023-09-30	8,783,685	29,974,400	29.30%
2023-06-30	8,895,156	24,006,549	37.05%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Eledon Pharmaceuticals, Inc. (ELDN) — SEC Financial Statements & Analysis

Eledon Pharmaceuticals, Inc. (ELDN) is a pharmaceutical preparations company, incorporated in DE. Eledon Pharmaceuticals, Inc. trades on Nasdaq as: ELDN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Eledon Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of 1.64x, a Price-to-Book (P/B) ratio of 13.56x (TTM), at a market cap of $447.71M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 1.64x
P/B TTM: 13.56x
Market Cap: $447.71M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Eledon Pharmaceuticals, Inc. in?

Eledon Pharmaceuticals, Inc. (ELDN) operates in the Pharmaceutical Preparations industry.

What is ELDN's market cap?

Eledon Pharmaceuticals, Inc. (ELDN) has a market capitalization of $447.71M as of 2026-06-30.

What exchange does ELDN trade on?

Eledon Pharmaceuticals, Inc. (ELDN) trades on the Nasdaq.

Where is Eledon Pharmaceuticals, Inc. incorporated?

Eledon Pharmaceuticals, Inc. is incorporated in DE.